Bayer will shift hemophilia drug work to Berkeley, but won't add jobs

Bayer AG will cut 12,000 jobs globally and shut a recently constructed hemophilia drug-making facility in Germany, consolidating manufacturing of its blood-clotting drugs in Berkeley. Bayer has no plans to recall people to the roughly 400 manufacturing-related jobs it has cut over the past year in Berkeley, the only unionized biotech workforce in the United States. But the moves disclosed Thursday allow Bayer to mop up excess capacity in response to a more-competitive hemophili a market — including…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news